Northern Trust Corp Has $19.24 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Northern Trust Corp lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 24.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 455,007 shares of the company's stock after acquiring an additional 89,707 shares during the quarter. Northern Trust Corp owned about 0.72% of Vera Therapeutics worth $19,242,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in VERA. Huntington National Bank bought a new stake in shares of Vera Therapeutics during the 4th quarter worth about $26,000. AlphaQuest LLC bought a new stake in Vera Therapeutics during the 4th quarter valued at approximately $34,000. KBC Group NV grew its holdings in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after buying an additional 1,387 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in Vera Therapeutics by 16.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after buying an additional 639 shares during the last quarter. Finally, Moors & Cabot Inc. acquired a new stake in Vera Therapeutics in the 4th quarter valued at approximately $220,000. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA traded down $0.08 during trading on Friday, reaching $21.25. 955,320 shares of the company traded hands, compared to its average volume of 780,251. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61. The firm has a market capitalization of $1.35 billion, a PE ratio of -8.14 and a beta of 1.28. The company's 50 day moving average is $23.63 and its two-hundred day moving average is $34.16.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period last year, the company posted ($0.56) earnings per share. As a group, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on VERA shares. Cantor Fitzgerald lowered their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. HC Wainwright initiated coverage on Vera Therapeutics in a research note on Monday, May 5th. They set a "buy" rating and a $75.00 price objective for the company. Wolfe Research initiated coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective for the company. Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, JPMorgan Chase & Co. decreased their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $63.33.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.